CRDL
Cardiol Therapeutics Inc.
Healthcare — Drug Manufacturers - Specialty & Generic
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Price History
Fundamentals
| Market Cap | $121.04M |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.33 |
| EPS (TTM) | $-0.27 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -173.96% |
| Debt/Equity | 0.48 |
| Recommendation | None |
| Analyst Target | $7.13 |
| Analysts | 4 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 50.0 |
| Beta | 0.48 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.71 |
| 52-Week Low | $0.88 |
| 50-Day Avg | $1.22 |
| 200-Day Avg | $1.11 |
| Avg Volume | 488.0K |
| Volume | 314.1K |
Performance Analysis
BULLISHCRDL shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:04 UTC
Back to Screener Export Report